News Briefing channel feed

Fortress Biotech takes out $60M loan for debt pur­pos­es; En­ta­sis pulls in $25M pri­vate place­ment for PhI­II tri­al

5 years ago

A nano-cap strug­gles to ride the IPO wave; Seat­tle Ge­net­ics gets a GSK mile­stone

5 years ago

Tizona com­pletes spin­out of can­cer pro­gram as part of Gilead buy­out; Dyne files for $100M IPO

5 years ago

ATAI adds MD­MA biotech to grow­ing list of psy­che­del­ic mak­ers; Aca­dia adds $52.5M up­front pain buy­out

5 years ago

Odonate an­nounces 'pos­i­tive' re­sults but faces in­vestor back­lash; Aslan is once again re­cruit­ing clin­i­cal tri­al par­tic­i­pants af­ter months-long wait amid the pan­dem­ic

5 years ago

Bio­Marin sub­mits NDA for con­tro­ver­sial achon­dropla­sia drug; Cell and gene ther­a­py boom sparks €49M buy­out

5 years ago

Eli Lil­ly part­ner Ab­Cellera ac­quires bis­pe­cif­ic plat­form; Te­va faces more law­suits, this time over opi­oid mar­ket­ing

5 years ago

Bushu plans $100 mil­lion ex­pan­sion for phar­ma­ceu­ti­cal in­spec­tion fa­cil­i­ty; RUC­DR breaks away from Rut­gers Uni­ver­si­ty, re­launch­es as IBX

5 years ago

Court hands No­var­tis win in Gilenya patent fight; US states seek $26B+ in opi­oid cri­sis law­suit

5 years ago

KKR health­care vet Jim Mom­tazee jump starts a new in­vest­ment firm; Bay­er signs up a top Chi­na biotech play­er to $645M deal

5 years ago

TG Ther­a­peu­tics scores pri­or­i­ty re­view for PI3Kδ in­hibitor; Gala­pa­gos search­es for IBD tar­gets in new pact

5 years ago

VBL an­nounces pos­i­tive PhI­II da­ta for ovar­i­an can­cer drug; Gene­Cen­tric part­ners with Janssen on blad­der can­cer

5 years ago

Har­mo­ny Bio­sciences sets terms on $100M IPO; FDA ac­cepts a Pro­tal­ix BLA for re­view

5 years ago

Eli Lil­ly teams with Pieris on HER2+ tu­mors; Op­di­vo + Yer­voy best chemo in mesothe­lioma

5 years ago

Ab­b­Vie set­tles in­sur­ance fraud suit, agrees to tweak nurse am­bas­sador pro­gram; CStone aims for NSCLC OK with pos­i­tive PhI­II da­ta

5 years ago

No­vo Nordisk ax­es 2 more obe­si­ty drugs as lead­ing drugs 'raise the bar'; Div­ing deep­er in­to R&D, CSL adds sup­port for biotech in­cu­ba­tor

5 years ago

My­ovant lands a fresh $200M loan as FDA mar­ket­ing de­ci­sion looms; Amarin goes it alone in Eu­rope

5 years ago

Karuna and In­cyte scrap pro­grams; More cash for the SPACs

5 years ago

Sanofi un­der for­mal in­ves­ti­ga­tion for De­pakine al­le­ga­tions; Beam li­cens­es CAR-T tech from Ox­ford Bio­med­ica

5 years ago

BioN­Tech and Re­gen­eron launch new melanoma col­lab; Har­bour Bio­Med finds in­cu­ba­tion part­ner

5 years ago

Bris­tol My­ers Squibb and blue­bird bio re­turn to FDA; Take­da gets a break­through nod

5 years ago

Trump, Big Phar­ma trade barbs over drug pric­ing EOs; BAR­DA gives Re­gen­eron $350M for Ebo­la drugs

5 years ago

Ab­b­Vie backs an Ital­ian start­up fo­cused on au­toim­mune dis­eases; Bio­Th­eryX ad­vances AML drug with $35M D round

5 years ago

Boehringer In­gel­heim beefs up vet port­fo­lio with GST buy­out; No­var­tis, Aus­tria to in­vest €150M in Eu­ro­pean man­u­fac­tur­ing deal

5 years ago
First page Previous page 37383940414243 Next page Last page
A service from the Financial Times